Ajanta Pharma Buyback – Review, Offer Details, Price, Dates, Size & more
Last Updated Date: Apr 24, 2022In this article, we will discuss the Ajanta Pharma Limited Buyback offer, buyback price, buyback size, Ajanta Pharma Buyback record date, company financial, buyback necessity, and its impact on the company.
To track the real-time share price of this Buyback, click on this link – Ajanta Pharma Share Price
Ajanta Pharma Buyback Details
| Buyback Type | Tender Offer |
| Buyback Opening Date | [●] |
| Buyback Closing Date | [●] |
| Buyback Offer Amount | Rs. 285.60 Cr/- |
| Buyback No. of Shares | 11,20,000 |
| Face Value | Rs. 2/- |
| Date of Buyback Approval | December 28, 2021 |
| Date of Public Announcement | [●] |
| Buy Back Price | Rs. 2,550/- |
| Buy Back Premium | 1.29% |
| Date of Board Meeting | December 28, 2021 |
Ajanta Pharma Buyback Opening and Closing Date
The starting and closing dates of this buyback are from [●] to [●].
Ajanta Pharma Buyback Cash Offer
The Cash Offer to Buy-back up to 11,20,000 fully paid-up equity shares of the Company of the face value of Rs.2 each.
Ajanta Pharma Buyback Record Date
The decided record date is January 14, 2022.
Ajanta Pharma Buyback Price
At a price of Rs.2,550/- per equity share.
Ajanta Pharma Buyback Size
The Buyback is for an aggregate amount not exceeding Rs. 285.60 Cr
Ajanta Pharma Buyback Acceptance Ratio
Find profit & profit percentages based on various acceptance rates. The profit is calculated based on 1000 shares.
| Acceptance Ratio | Total Shares Accepted | Buyback Price | Buyback Amount | Profit | Profit% |
| 20% | 200 | 1850 | 370000 | 66000 | 4.34% |
| 40% | 400 | 1850 | 740000 | 132000 | 8.68% |
| 60% | 600 | 1850 | 1110000 | 198000 | 13.03% |
| 80% | 800 | 1850 | 1480000 | 264000 | 17.37% |
| 100% | 1000 | 1850 | 1850000 | 330000 | 21.71% |
Profit is calculated from 27th November 2020 share price i.e. Rs.1520 per share of Ajanta Pharma Limited.
According to the above table, if a shareowner applies for 1000 shares of Ajanta Pharma Limited & gets 20% acceptance from the company, the owner of these 1000 shares will sell 200 shares @ Rs.1850 per share & receive Rs.66000 as profit amount & 4.34% profit percentage on selling these 200 shares back to the company.
Similarly, if the owner gets 60% acceptance of share from the company, the owner will sell 600 shares @ Rs.1850 & receive a profit of Rs.198000 @ 13.03% profit percentage.
Ajanta Pharma Limited Buyback Overview
The Company is a specialty pharmaceutical formulation company engaged in the development, manufacture, and marketing of qualified finished dosages.
The Company is focused on the branded generics market in India, Asia, and Africa, generics market in the USA besides Institutional segment in Africa.
This Company has seven (7) manufacturing facilities in India and Mauritius of which two (2) facilities in India have been approved by the US FDA.
The Company also has a research and development center for finished formulations and active pharmaceutical ingredient synthesis of different dosage forms.
The Equity Shares of the Company are listed on BSE and NSE since June 5, 2000, and May 29, 2000. The ISIN of the Equity Shares is INE031B01049.
Check other Buybacks with previous, upcoming, and active status
Company Finances – Ajanta Pharma Limited
The salient financial information of the Company, as extracted from the audited standalone financial statements for years ended March 31, 2020, March 31, 2019, and March 31, 2018, and limited review financial results for six months period ended September 30, 2020, is detailed below:
(Rs.in Crore)
| Key Financials | September 30, 2020 | March 31, 2020 | March 31, 2019 | March 31, 2018 |
| (Limited Review) | (*Audited) | (Audited) | (Audited) | |
| Revenue from Operations | 1,237.36 | 2,196.42 | 1,772.62 | 1,830.45 |
| Other Income | 99.34 | 184.2 | 102.15 | 73.01 |
| Total Income | 1,336.70 | 2,380.62 | 1,874.77 | 1,903.46 |
| Total Expenses (excluding finance cost & depreciation) | 813.09 | 1663.64 | 1291.41 | 1,283.64 |
| Finance Cost | 2.55 | 9.10 | 0.41 | 0.24 |
| Depreciation and amortization expenses | 54.06 | 91.29 | 69.9 | 57.14 |
| Exceptional Items: Expense / (Income) | 0.00 | (3.92) | 0.00 | 0.00 |
| Profit Before Tax | 467.00 | 612.67 | 513.05 | 562.44 |
| Tax Expenses | 126.09 | 171.54 | 121.29 | 134.92 |
| Profit/(Loss) discontinuing operation | 0.00 | *0.00 | 0.00 | 0.00 |
| Profit After Tax | 340.91 | 441.13 | 391.76 | 427.52 |
| Paid-up Equity Share Capital | 17.54 | 17.54 | *17.54 | 17.69 |
| Other Equity, excluding revaluation reserves & Misc. expenditures to the extent not written off | 2783.74 | 2,443.76 | 2,124.54 | 1,913.81 |
| Net worth, excluding revaluation reserves & Misc. expenditures to the extent not written off | 2,801.28 | 2,461.30 | 2,142.08 | 1,931.50 |
| Total Debt | 0.00 | 0.00 | *0.00 | 0.00 |
Ajanta Pharma Buyback Dates
| Date of the Board meeting held to approve the proposal for Buy-back of Equity Shares | December 28, 2021 |
| Date of publication of Public Announcement for the Buy-back | [●] |
| Record Date for determining the Buy-back Entitlement and the Eligible Shareholders | January 14, 2022 |
| Buy-back opens on / Buy-back Opening Date | [●] |
| Buy-back closes on / Buy-back Closing Date | [●] |
| Last date of verification by Registrar to Buy-back | [●] |
| Last date of intimation to the Stock Exchange regarding acceptance or non-acceptance of tendered Equity Shares by the Registrar and Manager to the Buy-back | [●] |
| Last date of settlement of bids on the Stock Exchange | [●] |
| Last date of return of unaccepted demat shares by Stock Exchange to Seller Member / Broker | [●] |
| Last date of extinguishment of Equity Shares bought back | [●] |
Necessity of Ajanta Pharma Limited Buyback
The Company’s management strives to increase the Shareholders’ value and the Buyback would result in the following:
The Buy-back is being undertaken by the Company to enhance shareholders’ value and improve the financial ratio. Additionally, the Buy-back is being undertaken for the following reasons:
i. The Buy-back will help the Company to distribute surplus funds to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to the shareholders;
ii. The Buy-back, which is being implemented through the Tender Offer as prescribed under the Buy-back Regulations, would involve a reservation of 15% of the Buy-back Size for small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would get classified as “Small Shareholders” as defined under Regulation 2(i)(n) of the Buy-back Regulations;
iii. The Buy-back will help in improving financial ratios like earnings per share, return on assets and return on equity calculated on the basis of financial statements, by reducing the equity base of the Company; and
iv. The Buy-back gives an option to the Eligible Shareholders to either choose to participate in the Buy-back and receive cash in lieu of their Equity Shares which are accepted under the Buy-back or choose not to participate in the Buy-back and get a resultant increase in their percentage shareholding in the Company post-Buy-back, without additional investment.
Find Latest Buybacks Offer, Performance and Financial details
Impact of Ajanta Pharma Limited Buyback on the Company
The Company believes that the Buyback is not likely to cause any material impact on the profitability/ earnings of the Company except a reduction in the amount available for investment, which the Company could have otherwise deployed towards generating investment income.
This shall impact the investment income earned by the Company, on account of reduced amount of funds available for investments.
The Company believes that the Buyback will not in any manner impair the ability of the Company to pursue growth opportunities or meet its cash requirements for business operations. The Buyback is expected to contribute to the overall enhancement of shareholder value and result in an increase in the return on equity of the Company.
The debt-equity ratio post Buyback will be compliant with the permissible limit of 2:1 prescribed by Section 68 of the Companies Act and Regulation 4(ii) of the Buyback Regulations, even if the response to the Buyback is to the extent of 100% (full acceptance).
Salient financial parameters consequent to the Buyback based on the audited standalone and consolidated financial statements as on March 31, 2020, of the Company are as under:
| Parameters | Standalone | Consolidated | ||
| Pre- Buyback | Post- Buyback | Pre- Buyback | Post- Buyback | |
| Net worth (Rs. in Crores) | 2,461.30 | 2,325.33 | 2,598.87 | 2,462.90 |
| Return on Net worth (%) | 17.92% | 18.97% | 18.00% | 18.99% |
| Basic Earnings Per Share (Rs.) (of Rs. 2 each) | 50.55 | 50.98 | 53.60 | 54.06 |
| Book Value per Share (Rs) | 282.06 | 268.74 | 297.83 | 284.64 |
| Price earning ratio | 27.03 | 26.80 | 25.49 | 25.28 |
| Total Debt/ Equity Ratio | 0.00 | 0.00 | 0.02 | 0.02 |
Basis of Calculating Ajanta Pharma Buyback Price
The Buyback price of Rs.2,550/- per Equity Share has been arrived at after considering various factors such as the average closing prices of the Equity Shares on the Stock Exchanges where the Equity Shares of the Company are listed, the net-worth of the Company and the impact of the Buyback on the key financial ratios of the Company.
More on Ajanta Pharma Buyback Price Calculation
The Buyback Offer Price of Rs.2,550/- per Equity Share represents:
- Premium of 16.80% on BSE and 16.72%% on NSE over the volume-weighted average price of the Equity Shares on BSE and NSE respectively for 3 months preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback;
- The premium of 17.40% on BSE and 17.29% on NSE over the volume-weighted average price of the equity Shares on BSE and NSE respectively for 2 weeks preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback;
- Premium of 16.39% on BSE and 16.23% on NSE over the closing market price of the Equity Shares on BSE and NSE as on the date of the intimation to BSE and NSE for the Board Meeting to consider the proposal of the Buyback.
Know more about other Buybacks and their Registrar details
Source of Funds for the Buyback
The Buyback shall be made out of the free reserves of the Company as at March 31, 2020 (i.e. the last audited financial statements available as on the date of Board Meeting recommending the proposal of 19 the Buyback).
The Company shall transfer from its free reserves a sum equal to the nominal value of the Equity Shares bought back through the Buyback to the Capital Redemption Reserve Account and the details of such transfer shall be disclosed in its subsequent audited balance sheet.
The funds for the Buyback will be met out of internally generated cash resources of the Company. The Company does not intend to raise additional debt for the explicit purposes of the Buyback. Accordingly, borrowed funds will not be used for the Buyback. However, if required, the Company may borrow funds in the ordinary course of its business.
Ajanta Pharma Limited – Manager to the Buyback
| Vivro Financial Services Private Limited Address: 607/608 Marathon Icon, Opp. Peninsula Corporate Park, Veer Santaji Lane, Off. Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013, Maharashtra, India Tel.:+91 22 6666 8040 | E-mail: investors@vivro.net | Website: www.vivro.net Contact Person(s): Mr. Anshul Nenawati / Mr. Jay Shah SEBI Registration Number: INM000010122 | Validity: Permanent CIN: U67120GJ1996PTC029182 |
Ajanta Pharma Limited – Registrar to the Buyback
| LINK INTIME INDIA PRIVATE LIMITED C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Contact Person: Mr. Sumeet Deshpande Tel: +91 22 4918 6200 Fax: +91 22 4918 6195 E-mail: ajantapharma.buyback2020@linkintime.co.in Website: www.linkintime.co.in SEBI Registration Number: INR000004058; Validity Period: Permanent CIN: U67190MH1999PTC118368 |
Ajanta Pharma Limited Contact Details
| Company Contact Details |
| AJANTA PHARMA LIMITED Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai – 400 067, Maharashtra, India CIN: L24230MH1979PLC022059 Contact Person: Mr. Gaurang Shah, Company Secretary Tel: +91 22 6606 1000 | Fax: +91 22 6606 1200 Email: investorgrievance@ajantapharma.com | Website: www.ajantapharma.com |
Ajanta Pharma Limited Buyback News
News 1 – letter of offer PDF [Download]
FAQs of Ajanta Pharma Buyback
What is the Ajanta Pharma Buyback Period?
Ajanta Pharma Buyback Period is briefly the time interval starting from the date of declaration of results of the postal ballot through remote e-voting i.e. NA. The period basically ends on the date of payment of consideration to Eligible Shareholders who participated in the Buyback, i.e. NA.
What type of buyback is Ajanta Pharma Buyback?
This company has chosen the route of Tender offer to repurchase the shares from the eligible shareholders. Tender offer route is one of the Two Routes generally chosen by the companies, i.e. Tender Offer and Open Market Through Stock Exchanges.
What is the Ajanta Pharma Buyback Offer?
Ajanta Pharma Buyback Offer refers to the number of shares the company plans to buy back from the eligible shareholders. Herein, the company proposes to buy back 11,20,000 Fully paid up Equity shares, adhering to the buyback price.
When Ajanta Pharma Buyback offer will start?
As per the released schedule, the Ajanta Pharma Buyback offer will start on NA. This is the opening date from when the Buyback will open for all shareholders. You will find the updated records of Ajanta Pharma Buyback at all times, we ensure you have access to the right data.
When is the closing date of Ajanta Pharma Buyback?
For ease in access to the dates and related aspects, we have segregated the closing date of Ajanta Pharma Buyback. The buyback would close on NA. The closing date is the last day for which the Buyback shall be open for the shareholders.
What is the offer price for Ajanta Pharma Buyback?
The amount at which the shares are taken back by the company is referred to as Ajanta Pharma Buyback offer price. Herein, each and every fully Paid-up equity share is priced at Rs.2,550, the price paid to each eligible shareholder.
What is the record date for Ajanta Pharma Buyback offer?
Record date of Ajanta Pharma Buyback is January 14, 2022. Record date is generally the day when eligible shareholders are declared. Furthermore, complying with Buyback regulations, a letter of offer and Tender form is sent to the eligible shareholders.
What is the issue size of Ajanta Pharma Buyback?
Ajanta Pharma Buyback Size is Rs.285.60 Cr and is the total worth of Equity Shares the company plans on taking back. This amount is obtained from the total number of equity shares, multiplied by the Buyback price.
What is the necessity for Ajanta Pharma Buyback?
Objective of the Ajanta Pharma Buyback is to enhance the total return made by equity shareholders. Herein, the excess funds are given to the equity shareholders, which are over and above its ordinary capital requirements and in excess of any current investment plans. Through buyback, the company will distribute the surplus cash to shareholders as per their holding proportion.
Who is the Registrar to Ajanta Pharma Buyback offer?
The designated registrar of Ajanta Pharma Buyback is LINK INTIME INDIA PRIVATE LIMITED. You can find all the details related to the registrar in this report and contact them if you have any queries. You can check the details of the registrar, contact person, email address, and more.
Who is the Manager to the Ajanta Pharma Buyback offer?
Manager to the Ajanta Pharma Buyback is Vivro Financial Services Private Limited. Manager basically ensures that the company following up buyback strictly adheres to and in conformity with the provisions of the Companies Act and Buyback Regulations.
How to check Ajanta Pharma’s buyback acceptance ratio?
Acceptance ratio is basically the proportion of shares the company accepts, to the final number of shares tendered. It refers to how much the company would buyback and how profitable it would be for you. You can also check how much profit (%) you will earn. Click on the link and check on the website page.
Where to find Ajanta Pharma Buyback Dates / Events?
You can check the table for the list of events, as designed for the buyback. This article is your one and final destination to check all the Ajanta Pharma Buyback information. You will encounter a section exclusively set to record the dates, in this article, referred to as Ajanta Pharma Buyback Dates.
What can be the Impact of Ajanta Pharma Buyback on the Company?
The Buyback will not in any manner impair the ability of the Company to pursue growth opportunities or meet its cash requirements for business operations. The Buyback is expected to contribute to the overall enhancement of shareholder value and result in an increase in the return on equity of the Company. This Buyback is being undertaken, inter alia, for helping the Company to return surplus cash to the Eligible Shareholders broadly in proportion to their shareholding.
Where to find complete details on Ajanta Pharma Buyback?
As mentioned already, this page would give you every single detail about this buyback. Also, you find the link to download the Draft / Letter of Offer. Each and every section is vividly and carefully placed, giving you insights into all major as well as minor aspects of the ratio. The article is also inclusive of all the links.
Market Guide
Featured Topics